| 37.77 -0.36 (-0.94%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 46.31  |
1-year : | 48.88 |
| Resists | First : | 39.65 |
Second : | 41.84 |
| Pivot price | 38.44  |
|||
| Supports | First : | 36.11 | Second : | 30.04 |
| MAs | MA(5) : | 38.65 |
MA(20) : | 38.28 |
| MA(100) : | 34.99 |
MA(250) : | 28.95 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.2 |
D(3) : | 53.5 |
| RSI | RSI(14): 45.6 |
|||
| 52-week | High : | 51.09 | Low : | 17.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SEPN ] has closed above bottom band by 30.9%. Bollinger Bands are 54.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 39.04 - 39.36 | 39.36 - 39.57 |
| Low: | 36.7 - 37.05 | 37.05 - 37.28 |
| Close: | 37.32 - 37.85 | 37.85 - 38.21 |
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Mon, 14 Sep 2026
Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich? - Yahoo Finance
Thu, 10 Sep 2026
Wells Fargo Sticks to Their Buy Rating for Septerna, Inc. (SEPN) - theglobeandmail.com
Thu, 10 Sep 2026
Septerna (SEPN) awards CMO 275,000 options at $37.37 - Stock Titan
Wed, 09 Sep 2026
Septerna (SEPN) Q2 2026 Earnings: $0.29 Per-Share Loss Beats Estimates by 33.26% as Stock Gains 3.28% - Analyst Drop Coverage - careplusvn.com
Tue, 11 Aug 2026
Stifel raises Septerna stock price target to $49 on SEP-479 outlook - Investing.com
Mon, 10 Aug 2026
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 2.641e+007 (%) |
| Held by Institutions | 3 (%) |
| Shares Short | 3,350 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.44e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -24.6 % |
| Operating Margin | -63 % |
| Return on Assets (ttm) | -7.2 % |
| Return on Equity (ttm) | -6.4 % |
| Qtrly Rev. Growth | 22 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 106 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.87e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|